이연제약
102460KOSPI의약품 제조업48.3 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
Il Yeon Pharm is a specialized pharmaceutical company established in 1964, focusing on the manufacturing and sales of prescription drugs, original pharmaceuticals (e.g., CT contrast agent 'Optirey'), and bulk drugs. Its Chungju facility, certified for biopharmaceutical production and CMO services, supports new drug pipeline development through a production-platform-based R&D model. However, as of 2024, the company reported sales of 145.9 billion won, an operating loss of 30.3 billion won, and a net loss of 29.6 billion won, indicating the need for improved profitability.
Number of Employees
457people
Average Salary
76.4M KRW
Score Calculation Basis
Detailed Financial Score
Higher than industry avg (caution)
Well below industry avg
3.7x industry avg (risky)
Avg ▼1.7% (2-year basis)
Avg ▼19193.7% (2-year basis)
Avg ROE -3.2% (declining, 3yr)
Detailed News Sentiment
- Positive이연제약 “NG101 중용량, 주사 횟수 90% 감소… 시력도 개선"
이연제약의 NG101 임상 결과, 중용량에서도 주사 횟수가 크게 감소하고 시력 개선 효과가 확인되어 긍정적인 시장 반응 예상.
- Positive이연제약 "안과 신약 임상서 '저용량·고성능' 확인…압도적 경쟁력"
이연제약의 엘리시젠이 망막질환 치료제 NG101의 임상 결과에서 저용량 투여에도 불구하고 뛰어난 성능을 보여주며 경쟁력을 입증했다.
- Positive엘리시젠, 美 ASRS 2026서 황반변성 유전자치료제 NG101 임상...
이연제약의 파트너사 엘리시젠의 NG101 임상 결과 발표로 이연제약 관련 긍정적 기대감 증가.
Detailed Momentum
Near 52w low (4%, downtrend)
1m 1.02% (flat)
Volume increasing
